KIFFIK Biomedical Recognized as Top Biomarker Access Technology 2026 by Life Sciences Review
Publication Features KIFFIK Chief Scientific Officer Gino Martini, PhD MIAMI, FL / ACCESS Newswire / November 10, 2026 / KIFFIK...
Pharmaceutical
Zomedica Announces “Third Friday at Four” Webinar on November 20, 2026: The People Behind Zomedica – Seven Guiding Principles in Action, and Q3 Financial Results
November session will introduce the experienced team behind Zomedica's seven guiding principles, from R&D and manufacturing to finance and the...
TECregen Strengthens Management Team and Board to Advance Thymus Regeneration and Lead Program TEC001
Elisabeth Svanberg, MD, PhD, appointed Chief Medical Officer, adding extensive global clinical-development and regulatory expertiseThomas Hanke, PhD, joins the Board,...
Trogenix appoints industry veterans John Young as Chair and Josh Murray as Non-Executive Director to support global strategy, commercial foundation and patient access
John brings more than 35 years of operational and commercial leadership with extensive experience in bringing medicines to market at...
Roche presents new data across pharmaceuticals and diagnostics from its growing Alzheimer’s disease portfolio at CTAD 2026
Updated Phase Ib/IIa Brainshuttle™ AD study data for trontinemab demonstrating rapid amyloid removal dynamics and changes in key biomarkers Phase III...
Syndax Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
NEW YORK, Nov. 09, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies,...
Digbi Health Reports 18.4% Weight Loss With Tirzepatide, Challenges One-Size-Fits-All GLP-1 Care
Precision Biology makes GLP healthier. Precision biology makes food healthier. Real-world results from 3,181 members across 10 employers, to be...
Mesa Labs Announces Second Quarter Fiscal Year 2027 Results and Issues First Full-Year Guidance
LAKEWOOD, Colo., Nov. 09, 2026 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) (“Mesa” or “the Company”), a global leader in...
Structure Therapeutics Reports Third Quarter 2026 Financial Results and Recent Highlights
Phase 3 ACCOMPLISH-1 and ACCOMPLISH-2 registrational clinical trials of aleniglipron (oral small molecule GLP-1 receptor agonist) enrolling; topline data expected...
Corvus Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference in London
SOUTH SAN FRANCISCO, Calif., Nov. 09, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today...
Atea Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Business Update
Phase 3 C-BEYOND Trial Achieved Primary and Secondary Endpoints, Reinforcing Potential Best-in-Class Profile of BEM/RZR for Treatment of Hepatitis C...
Zymeworks Provides Corporate Update and Reports Third Quarter 2026 Financial Results
Zymeworks CEO Kenneth Galbraith speaks about the company’s progress for in Q3 2026 2026 financial guidance raised to a total...
OraSure Announces Third Quarter 2026 Financial Results; Strategic Execution Drives Double-Digit Year-Over-Year Growth and Margin Expansion
14% year-over-year revenue growth in the quarter highlights effectiveness of return-to-growth strategyGAAP gross margin improved by over 170 bps vs....
Rani Therapeutics Reports Third Quarter 2026 Financial Results; Provides Corporate Update
~ Accepted into the U.S. FDA’s Emerging Technology Program (ETP), enabling early FDA engagement to support development of the RaniPill®...
Maze Therapeutics Reports Third Quarter 2026 Financial Results and Recent Highlights
Enrollment completed in Phase 2 HORIZON trial of MZE829; data from all three cohorts expected in early 2027 Enrollment ongoing...
Zentalis Pharmaceuticals Reports Third Quarter 2026 Financial Results and Business Updates
DENALI Part 1b survival data strengthen azenosertib's position as the potential first-in-class oral, non-chemotherapy, non-ADC therapy in pivotal development for...
MapLight Therapeutics to Participate in Upcoming Investor Conference
SAN FRANCISCO and BOSTON, Nov. 09, 2026 (GLOBE NEWSWIRE) -- MapLight Therapeutics, Inc. (Nasdaq: MPLT) today announced that members of...
PetMeds Announces Strategic Partnership with Pet Supermarket to Expand Pharmacy Offering Across Retail and Digital Channels
DELRAY BEACH, Fla., Nov. 09, 2026 (GLOBE NEWSWIRE) -- PetMed Express, Inc., dba PetMeds and parent company of PetCareRx (Nasdaq:...
Apollomics Reports First-Half 2026 Financial Results
Phase 2 studies ongoing to advance global development of vebreltinib, a highly potent, de-risked and differentiated c-MET Inhibitor with best-in-class...
Trevi Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Updates
Initiated Phase 3 OCEAN-2 trial for patients with IPF-related chronic cough in the third quarter; both Phase 3 OCEAN trials...